Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft
function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal
transplant recipients.